Vij Ridhima, Prossin Alan, Tripathy Mallika, Kim Hosu, Park Hyeonggeun, Cheng Thanh, Lotfi Djamchid, Chang Donna
Hope Biosciences Research Foundation, Sugar Land, TX, United States.
McGovern Medical School at UTHealth Houston, TX, United States.
Front Neurol. 2023 Sep 27;14:1257080. doi: 10.3389/fneur.2023.1257080. eCollection 2023.
Parkinson's disease (PD) is a neurodegenerative disease that involves the loss of dopaminergic neurons in the substantia nigra pars compacta of the basal ganglia. Clinically, patient presentation involves a combination of motor and non-motor symptoms characterized by progressive worsening over time and significant decreases in overall quality-of-life. Despite there being no fully restorative cure for PD, Mesenchymal Stem Cell (MSC) therapy offers promising therapeutic potential. Here, we report a case of a 77-year-old female, living with idiopathic Parkinson's Disease for over 17 years. The patient received multiple infusions of autologous Hope Biosciences adipose-derived MSCs (HB-adMSCs). A total of 26 infusion treatments of HB-adMSCs were administered over the course of ~2 years that resulted in marked improvements in her typical Parkinsonian symptoms, as demonstrated by the decreases in her UPDRS (Unified Parkinson's Disease Rating Scale) scores. Changes in clinical scores mirrored concurrent changes in regional brain metabolism as quantified by FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography), compared to baseline. Long-term, multiple infusions of HB-adMSCs were safely tolerated by the patient without any serious adverse events. Further research is needed to evaluate the safety and efficacy of HB-adMSC therapy for the treatment of PD patients.
帕金森病（PD）是一种神经退行性疾病，涉及基底神经节黑质致密部多巴胺能神经元的丧失。临床上，患者的表现包括运动和非运动症状的组合，其特征是随着时间的推移逐渐恶化，总体生活质量显著下降。尽管目前尚无完全治愈帕金森病的方法，但间充质干细胞（MSC）疗法具有广阔的治疗潜力。在此，我们报告一例77岁女性患者，患有特发性帕金森病超过17年。该患者接受了多次自体Hope Biosciences脂肪来源间充质干细胞（HB-adMSCs）输注。在约2年的时间里，共进行了26次HB-adMSCs输注治疗，结果显示她的典型帕金森症状有显著改善，这通过她的统一帕金森病评定量表（UPDRS）评分降低得以体现。与基线相比，临床评分的变化反映了通过氟脱氧葡萄糖正电子发射断层扫描（FDG-PET）量化的局部脑代谢的同步变化。长期多次输注HB-adMSCs患者耐受性良好，未出现任何严重不良事件。需要进一步研究来评估HB-adMSC疗法治疗帕金森病患者的安全性和有效性。
